Esperion Therapeutics, Inc. (NASDAQ:ESPR) recovered 411.49% of its value since hitting low of $43.78. The recent move of -7.91% drop pushed the stock to close at $48.08 when trading ended on Oct. 18, 2017. At recent session, the prices were hovering between $48.08 and $50. This company shares are 26.56% off its target price of $60.85 and the current market capitalization stands at $1.27B. The recent change has given its price a -4.56% deficit over SMA 50 and -16.24% deficit over its 52-week high. The stock witnessed -3.01% declines, -1.48% declines and 28.62% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ESPR’s volatility during a week at 5.13% and during a month it has been found around 4.08%.Esperion Therapeutics, Inc. (ESPR) Top Holders
Institutional investors currently hold around $1.21 billion or 0% in ESPR stock. Look at its top three institutional owners. Meditor Group Ltd owns $119.82 million in Esperion Therapeutics, Inc., which represents roughly 9.43% of the company’s market cap and approximately 9.94% of the institutional ownership. Similar statistics are true for the second largest owner, Pentwater Capital Management Lp, which owns 1,988,000 shares of the stock are valued at $103.79 million. The third largest holder is Bb Biotech Ag, which currently holds $79.02 million worth of this stock and that ownership represents nearly 6.22% of its market capitalization.
At the end of September reporting period, 68 institutional holders increased their position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by some 6,271,919 shares, 64 decreased positions by 1,890,599 and 16 held positions by 14,937,691. That puts total institutional holdings at 23,100,209 shares, according to SEC filings. The stock grabbed 28 new institutional investments totaling 1,084,689 shares while 13 institutional investors sold out their entire positions totaling 529,219 shares.Esperion Therapeutics, Inc. (NASDAQ:ESPR) Insider Trades
Multiple company employees have indulged in significant insider trading. Esperion Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Goldstein Dov A Md has sold 800,000 shares of Esperion Therapeutics, Inc. (ESPR) in trading session dated Mar. 22, 2017. These shares are worth $33,328,000 and were traded at $41.66 each. The SEC filing shows that Janney Daniel performed a sale of 350,000 shares. The Director disposed these shares by way of transaction on Mar. 21, 2017. The company’s shares were given away at $45.8 per share worth to an income of some $16,030,000 on account of Janney Daniel.
Director, Omenn Gilbert S, purchased 1,000 common shares of Esperion Therapeutics, Inc. (ESPR) in the open market. In a transaction dated Mar. 21, 2017, the shares were bought at an average price of $42.26, giving away a sum of $42,260. After this purchase, 11,000 common shares of ESPR are directly owned by the insider, with total stake valued at $528,880.
In the transaction dated Nov. 01, 2016, the great number of shares acquired came courtesy the COO; Lalwani Narendra D. added a total of 5,000 shares at an average price of $9.93, amounting to approximately $49,650. The insider now directly owns 5,000 shares worth $240,400.Esperion Therapeutics, Inc. (ESPR) Analyst Guide
Several analysts have released their opinion on Esperion Therapeutics, Inc. (NASDAQ:ESPR), with 6 analysts believing it is a strong buy. Whereas 3 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.67 average brokerage recommendation.